INTRODUCTION
============

Atopic dermatitis (AD) is a common infant or early childhood disease for which genetic factors may create a disposition and is triggered by a variety of antigens. AD is characterized by chronic or relapsing inflammatory dermatitis[@B1]. Atopy is described as \"a personal or familial tendency to produce IgE antibodies in response to low doses of allergens, usually proteins, and to develop typical symptoms such as asthma, rhinoconjunctivitis, or AD[@B2].\" The prevalence of AD has increased in with industrialization[@B3]. Thus, new approaches have attracted interest in the treatment of AD.

While probiotic means \"for life,\" allergic diseases (AD, allergic rhinitis, asthma, etc.) have been demonstrated in the treatment of many systemic diseases[@B4]. In this study, we have examined the clinical and anti-inflammatory effects of probiotic supplementation in pediatric patients with AD.

MATERIALS AND METHODS
=====================

Forty pediatric patients (23 males and 17 females) aged 1\~13 years participated in the study between October 2007 and April 2008. All children met the diagnostic criteria for AD as defined by Hanifin and Rajka[@B5]. The inclusion criteria were: a moderate to severe Scoring Atopic Dermatitis (SCORAD) index score[@B6],[@B7]; being 1\~13 years of age; absence of any other disease; having used no medication including antihistamines and corticosteroids for fourteen days prior to the study; and absence of gastrointestinal malabsorption.

Patients were referred to a nurse who was involved in the study to receive either probiotics or placebo. The nurse randomized each patient to two different treatment groups using the closed-envelope method. The authors had no role in the treatment decision and were blinded to the treatment groups. In this randomized double-blind, placebo-controlled study, patients were assigned to one of two groups, probiotics (Group 1) or placebo (Group 2). Group 1 (n=20) received two bags containing 2×10^9^ of four types of probiotic bacteria (*Bifidobacterium bifidum*, *Lactobacillus acidophilus*, *Lactobacillus casei*, and *Lactobacillus salivarius*) made by a commercially available supplementation (proBiotik® pur, Ella Farma, Münster, Germany), while those in Group 2 (n=20) received skim milk powder (Dairy Inc., Enka Milk Joint Stock Company, Turkey) and dextrose (Havana Chemistry, Pharmaceutical Medical Limited Company, Istanbul, Turkey) daily for a total of eight weeks.

Blood samples collected at baseline and ten weeks later were followed by storing plasma frozen at -80℃ until all cytokine analyses were performed. Total immunoglobulin E (IgE) levels were analyzed using total and 3gAllergy™ assays (Immulite 2,000 Immunoassay System, Siemens Healthcare Diagnostics, Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA), following the manufacturer\'s instructions. Eosinophil cationic protein (ECP) and cytokine levels were determined using enzyme-linked immunosorbent assay (BioSource International, Inc., Camarillo, CA, USA) using a Triturus® System (Grifols International S.A., manufactured by Grifols-Quest Inc.).

The study protocol followed the Declaration of Helsinki and included written consent by the parents or guardians of the participating patients. The study was approved by the Drug Research Ethics Committee and was supported by the Scientific Research Projects.

Statistical analysis
--------------------

All analyses were conducted using SPSS 11.5 statistical program (SPSS Inc., Chicago, IL, USA). A ratio test was applied to compare the proportion of patients in groups by age and sex. Pre- and post-treatment differences of serum cytokines, total IgE levels, ECP, and changes in SCORAD indices were compared using a paired t-test. *p*-values\<0.01 were considered statistically significant.

RESULTS
=======

One female patient in the placebo group failed to attend her follow-up visits resulting in withdrawal from the study. Comprising 58.9% of the patients, 23 males (aged 1\~12 years, mean \[standard deviation, SD\] 7.6±3) and 16 females (aged 1\~13 years, mean \[SD\] 9.3±3.2) completed the study.

The SCORAD index changed from 35.4±13.4 to 12.4±7.2 and from 28.1±6.1 to 15.3±5.1 in the probiotic and placebo groups, respectively. The post-treatment decrease in the SCORAD index in the probiotic group was greater than the decrease in the placebo group, a difference that was statistically significant (*p*=0.0015; [Table 1](#T1){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}).

As seen in [Fig. 1](#F1){ref-type="fig"}, there was a decrease in the serum interleukin (IL)-5, IL-6 and interferon (IFN)-γ levels of the probiotic group after treatment. The difference between the post-treatment decreases in cytokines IL-5 (*p*=0.0012) and IL-6 (*p*=0.0016) and IFN-γ (*p*=0.0011) was statistically significant compared to the difference in decreases of these cytokines in the placebo group. The difference between the rates of post-treatment decreases in the serum levels of IL-2 (p=0.023), IL-4 (*p*=0.67), IL-10 (*p*=0.013), ECP (*p*=0.021), and tumor necrosis factor-α (TNF-α; *p*=0.437) and the rates of post-treatment decrease of these cytokines in the placebo group did not have statistical significance.

The serum total IgE level decreased from 427±500 IU/ml to 281.9±405 IU/ml in the probiotic group. In the placebo group, the serum total IgE increased from 337.3±298 IU/ml to 347.7±271.3 IU/ml. The difference between the post-treatment serum IgE levels of the probiotic group and those of the placebo group was statistically significant (*p*=0.0035).

DISCUSSION
==========

There is a growing interest in using probiotic supplements not only by consumers for its health-promoting effects on a daily basis but also by health care professionals for its efficacy as a supplement and therapeutic product to treat a variety of medical conditions[@B8]. Probiotics affect allergic conditions on a number of levels. In the intestinal system, they inhibit the epithelial and mucosal adherence of pathogens and prevent their invasion through the epithelium[@B9]. Probiotics compete with pathogens for limited loci by their ability to adhere to intestinal epithelium and mucus. They also inhibit the proliferation of pathogens by consuming the nutrients in the intestine. Furthermore, the antibacterial potential of certain probiotic strains involves secretion of hydrogen peroxide, organic acids, and bacteriocins that inhibit the growth of pathogens. Hydrolytic enzymes contribute to the increase of free fatty acids, short chain fatty acids, lactic acid, propionic acid, and butyric acid in the intestinal lumen, thus setting up an appropriate pH. Probiotics alter mucosal immunity considerably. This involves an increase in antibody production and activities of phagocytes and natural killer cells, modulation of the nuclear factor-κB pathway, and induction of T-cell apoptosis[@B10]. In addition, probiotics have been shown to modify the structure of potential allergens that cause allergic diseases and alleviate their immunogenicity[@B11].

Our results demonstrated an improved SCORAD index in both groups, but with higher levels in the probiotic group (65%) than in the placebo group (46%). In the probiotic group, a greater decrease of SCORAD index scores was shown after treatment in patients with high SCORAD index scores. However, this difference did not reach a statistically significant level (*p*=0.0015). SCORAD index of AD patients were evaluated before and after an eight-week intervention using a combination of the probiotics *Lactobacillus paracasei* Lpc-37, *Lactobacillus acidophilus* 74-2, and *Bifidobacterium animalis* subsp. *lactis* DGCC 420. It decreased by 15.5% in the probiotic group, while the decrease was only 8% in the placebo group[@B12]. In nine of thirteen randomized controlled trials studying the effectiveness of probiotics in the treatment or prevention of AD in children, the SCORAD index changed after one- or two-month probiotic administration[@B13]. There are other studies on the probiotic intervention indicating favorable results in the SCORAD index of AD patients[@B14]-[@B19].

The serum total IgE level decreased from 427±500 IU/ml to 281.9±405 IU/ml in the probiotic group. In the placebo group, the serum total IgE increased from 337.3±298 IU/ml to 347.7±271.3 IU/ml. A significant difference was found between the probiotic and placebo groups regarding total IgE levels (*p*=0.0035).

Our study showed probiotics to be effective in reducing AD patients\' serum IL-5, IL-6, and IFN-γ levels. A double-blind, placebo-controlled study, however, found no clinical or immunological effects of probiotics of the Lactobacillus strain in serum IL-4, IL-5, and IFN-γ levels in infants with AD compared with the placebo group after three months of treatment[@B20]. Another double-blind, placebo-controlled study of 230 infants with atopic eczema/dermatitis syndrome showed no difference in clinical signs and serum IgE levels for the Lactobacillus GG-administered group and the placebo group[@B21]. Other clinical studies did not report any difference in cytokine levels after treatment with probiotics[@B13],[@B22].

As a result, our study found probiotics effective in reducing AD patients\' SCORAD index, serum IL-5, IL-6, IFN-γ, and total serum IgE levels but not effective in reducing serum IL-2, IL-4, IL-10, ECP, and TNF-α levels. The impact of probiotics on SCORAD indices is thought to be reduced by modification of immunogenicity of potential allergens. Probiotics are effective in the pathogenesis of AD through their effects such as restoring the mucosal barrier function in the intestines, degrading food antigens, regulating the intestinal microbial composition and activities, and stimulating the production of secretory IgA[@B23]. They also block Th2 allergic response by stimulating Th1 response[@B13],[@B23]-[@B26]. Probiotics regulate local and systemic immunity and thus alleviate the severity of clinical symptoms.
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SCORAD: SCORing Atoptic Dermatitis, BT: before treatment, SD: standard deviation, AT: after treatment, IL-2: interleukin-2, IL-4: interleukin-4, IL-5: interleukin-5, IL-6: interleukin-6, IL-10: interleukin-10, TNF-α: tumor necrosis factor-α, IFN-γ: interferon-γ, ECP: eosinophil cationic protein, IgE: immunoglobulin E. ^\*^Statistical used paired t-test for testing. *p* values\<0.05 were considered statistically significant.
